New vaccine design developed to protect against Ebola virus
Researchers have designed a new nanoparticle-based vaccine against Ebola that has shown promise in mice and rabbits.
List view / Grid view
Researchers have designed a new nanoparticle-based vaccine against Ebola that has shown promise in mice and rabbits.
Having synthesised the curcusone D compound, researchers demonstrated its promise as the first BRAT1 inhibitor, making it a potential cancer therapy.
A novel machine learning method can explain how glycans stabilise proteins, aiding the discovery and design of protein-based drugs.
A new vaccine is effective at preventing opioid overdose from fentanyl and carfentanil in rodents, according to a new study.
By combining natural killer cells with a new molecule called Sialyl-Lewis X, researchers were able to treat lymphoma in mice.
Scientists have created a drug discovery platform that enables the discovery and optimisation of RNA-targeting compounds.
This article lists three of the most recent advances in pre-clinical HIV research and vaccine development.
Using cryo-electron microscopy and site-specific mass spectrometry, researchers have mapped the glycans that shield HIV from the immune system.
Researchers have discovered how cone cells in the retina send information to the brain, which could be used in the development of treatments for blindness.
Researchers have shown that factoring in valency to vaccine design can improve the number of antibody binding sites on an antigen.
Researchers have discovered compounds able to restart production of VEGF-A in cellular models, which rebuilds blood vessels and muscle in damaged heart tissue.
Scientists have developed a synthetic biology process using enzymes to create three families of terpenes, potential starting points for new drugs.
The SARS-CoV-2 Spike protein from a COVID-19 vaccine candidate has been characterised by researchers, supporting the neutralising antibody response it elicits.
Newly discovered antibodies found in the blood of recovered COVID-19 patients could provide robust protection against SARS-CoV-2, say researchers.
The interaction between a SARS antibody called CR3022 and the COVID-19 coronavirus has been mapped by researchers, revealing a viral vulnerability.